4DMT Q3 2023 net loss narrows to $10.3M; cash $320M, runway into H1 2026; clinical progress across pipeline

4D Molecular Therapeutics, Inc.

2023-Q3 EPS reported -$1.81 revenue$20,742,000

Net loss of $10.3M versus $25.7M in Q3 2022; decrease primarily due to $20M upfront from Astellas License Agreement.
Cash, cash equivalents and marketable securities $320M as of Sep 30, 2023, up from $218M at Dec 31, 2022; runway into first half of 2026.
Completed enrollment of 4D-150 PRISM Phase 2 Dose Expansion for wet AMD nearly two quarters ahead of schedule; interim data expected early 2024.
Received EMA PRIME designation for 4D-150; reached agreement with FDA on plan to lift clinical hold on 4D-310 for Fabry disease cardiomyopathy.
R&D expenses rose to $25.1M from $18.9M driven by clinical trial progression and higher headcount; G&A expenses $9.1M versus $8.1M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

4D Molecular Therapeutics, Inc. reported financial results for the three months ended September 30, 2023.

Period: the three months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062109

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.